The Relative Strength (RS) Rating for Guardant Health climbed into a new percentile Thursday, with a rise from 80 to 85.
Risk Management In The Stock Market: How Much Money To Invest Now
This unique rating measures technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks matches up against the rest of the market.
History reveals that the stocks that go on to make the biggest gains tend to have an RS Rating of above 80 as they begin their biggest price moves.
While Guardant Health is not near a proper buy zone right now, see if it goes on to form and break out from a proper consolidation.
The company showed 0% earnings growth last quarter. Sales gains came in at 31%.
Guardant Health earns the No. 14 rank among its peers in the Medical-Services industry group. Hims & Hers Health, GeneDx Holdings and Progyny are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
